Amneal Pharmaceuticals, Inc.
AMRX
$4.66
$0.358.12%
| Weiss Ratings | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.22 | |||
| Price History | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.15% | |||
| 30-Day Total Return | 24.21% | |||
| 60-Day Total Return | 14.32% | |||
| 90-Day Total Return | 42.24% | |||
| Year to Date Total Return | 104.27% | |||
| 1-Year Total Return | 77.37% | |||
| 2-Year Total Return | 3.36% | |||
| 3-Year Total Return | 6.68% | |||
| 5-Year Total Return | -76.31% | |||
| 52-Week High % Change | -1.69% | |||
| 52-Week Low % Change | 275.81% | |||
| Price | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.74 | |||
| 52-Week Low Price | $1.24 | |||
| 52-Week Low Price (Date) | Mar 28, 2023 | |||
| 52-Week High Price (Date) | Aug 07, 2023 | |||
| Valuation | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $1.43B | |||
| Enterprise Value | 4.00B | |||
| Price/Earnings (TTM) | 76.39 | |||
| Earnings Per Share (TTM) | 0.06 | |||
| Earnings Per Share Growth | -106.95% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.31 | |||
| Price/Book (Q) | 2.17 | |||
| Enterprise Value/Revenue (TTM) | 1.68 | |||
| Price | $4.31 | |||
| Enterprise Value/EBITDA (TTM) | 7.83 | |||
| Enterprise Value/EBIT | 14.41 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 159.691M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 908 947 3120 | |||
| Address | 400 Crossing Boulevard Bridgewater, NJ 08807 | |||
| Website | amneal.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 11.63% | |||
| Profit Margin | 0.43% | |||
| Management Effectiveness | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.59% | |||
| Return on Equity | 19.00% | |||
| Income Statement | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $2.39B | |||
| Total Revenue (TTM) | $2.39B | |||
| Revenue Per Share | $14.94 | |||
| Gross Profit (TTM) | $857.74M | |||
| EBITDA (TTM) | $511.26M | |||
| EBIT (TTM) | $277.74M | |||
| Net Income (TTM) | $10.32M | |||
| Net Income Avl. to Common (TTM) | $10.32M | |||
| Total Revenue Growth (Q YOY) | 13.65% | |||
| Earnings Growth (Q YOY) | 1,147.41% | |||
| EPS Diluted (TTM) | $0.06 | |||
| EPS Diluted Growth (Q YOY) | 400.00% | |||
| Balance Sheet | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $92.05M | |||
| Cash Per Share (Q) | $0.58 | |||
| Total Current Assets (Q) | $1.46B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | $191.38M | |||
| Current Ratio (Q) | 1.914 | |||
| Book Value Per Share (Q) | $2.14 | |||
| Total Assets (Q) | $3.69B | |||
| Total Current Liabilities (Q) | $760.60M | |||
| Total Debt (Q) | $2.80B | |||
| Total Liabilities (Q) | $3.50B | |||
| Total Common Equity (Q) | $330.86M | |||
| Cash Flow | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -$48.96M | |||
| Cash from Financing (TTM) | -$133.91M | |||
| Net Change in Cash (TTM) | -$284.00K | |||
| Levered Free Cash Flow (TTM) | $151.72M | |||
| Cash from Operations (TTM) | $186.46M | |||
